High-bioactivity microfluidic immunosensing platform for electrochemiluminescence determination of CYFRA 21-1 with the introduction of Fe3O4@Cu@Cu2O

Relying on the electrochemiluminescence (ECL) and microfluidic technology, an immunosensor chip with high bioactivity was designed for sensitive determination of cytokeratin 19 fragment 21-1 (CYFRA 21-1). The mesoporous nanomaterial Fe3O4@Cu@Cu2O as the co-reaction accelerator was used to catalyze the S2O82- to produce more SO4 center dot- to achieve the amplification of the ECL signal. In fact, the generating of SO4 center dot- could not only be done with the aid of the reversible cycles of Fe2+ and Fe3+ and Cu+ and Cu2+, but could be achieved also through the catalase-like function of Fe3O4. What is more, it has also been proved that Fe3O4@Cu@Cu2O exhibited better catalytic performance than single Fe3O4, Cu2O, and Cu@ Cu2O, which supported its application in this system. In addition, a portable microfluidic immunosensor chip for CYFRA 21-1-sensitive determination was assembled, which showed high selectivity, sensitivity, and strong universality in clinical cancer screening and diagnosis. It should be noted that HWRGWVC (HWR) was introduced as the antibody fixator to improve the incubation and binding efficiency of the antibody, which increased the ECL intensity and improved the sensitivity of the immunosensor. This strategy provided a new idea for cancer identification and diagnosis in clinical medicine.

Automated summary

A sensitive immunosensor chip was designed using microfluidic technology and electrochemiluminescence (ECL) to detect cytokeratin 19 fragment 21-1 (CYFRA 21-1). The use of mesoporous nanomaterial Fe3O4@Cu@Cu2O as a co-reaction accelerator and introduction of HWRGWVC as an antibody fixator improved the sensitivity and amplification of the ECL signal, providing a new strategy for cancer identification and diagnosis in clinical medicine.